First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda por Poon, A, Ndashimye, E, Avino, M, Gibson, R, Kityo, C, Kyeyune, F, Nankya, I, Quiñones-Mateu, M, Arts, E, The Ugandan Drug Resistance Study Team, Hamers, R

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the... por Paton, N, Kityo, C, Thompson, J, Nankya, I, Bagenda, L, Hoppe, A, Hakim, J, Kambugu, A, van Oosterhout, J, Kinconco, M, Bertagnolio, S, Easterbrook, P, Mugyenyi, P, Walker, A

Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa por Boender, T, Kityo, C, Boerma, R, Hamers, R, Ondoa, P, Wellington, M, Siwale, M, Nankya, I, Kaudha, E, Akanmu, A, Botes, M, Steegen, K, Calis, J, Rinke de Wit, T, Sigaloff, K

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational anal... por Szubert, A, Prendergast, A, Spyer, M, Musiime, V, Musoke, P, Bwakura-Dangarembizi, M, Nahirya-Ntege, P, Thomason, M, Ndashimye, E, Nankya, I, Senfuma, O, Mudenge, B, Klein, N, Gibb, D, Walker, A

Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial por Musiime, V, Kasirye, P, Naidoo-James, B, Nahirya-Ntege, P, Mhute, T, Cook, A, Mugarura, L, Munjoma, M, Thoofer, N, Ndashimye, E, Nankya, I, Spyer, M, Thomason, M, Snowden, W, Gibb, D, Walker, A, ARROW Trial Team

HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa por Kityo, C, Thompson, J, Nankya, I, Hoppe, A, Ndashimye, E, Warambwa, C, Mambule, I, van Oosterhout, J, Wools-Kaloustian, K, Bertagnolio, S, Easterbrook, P, Mugyenyi, P, Walker, A, Paton, N, For the Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST)Trial Team